CN105497876B - 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 - Google Patents

神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 Download PDF

Info

Publication number
CN105497876B
CN105497876B CN201410529437.4A CN201410529437A CN105497876B CN 105497876 B CN105497876 B CN 105497876B CN 201410529437 A CN201410529437 A CN 201410529437A CN 105497876 B CN105497876 B CN 105497876B
Authority
CN
China
Prior art keywords
ventricular
neuregulin
incidence
arrhythmia
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410529437.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105497876A (zh
Inventor
周明东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zensun Shanghai Science and Technology Ltd
Original Assignee
Zensun Shanghai Science and Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55580273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105497876(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zensun Shanghai Science and Technology Ltd filed Critical Zensun Shanghai Science and Technology Ltd
Priority to CN201410529437.4A priority Critical patent/CN105497876B/zh
Priority to US15/513,939 priority patent/US10441633B2/en
Priority to JP2017516166A priority patent/JP2017530127A/ja
Priority to CA2961813A priority patent/CA2961813A1/en
Priority to EP15845381.1A priority patent/EP3199174B1/en
Priority to PCT/CN2015/088972 priority patent/WO2016045493A1/zh
Priority to CN201580050316.4A priority patent/CN110337304A/zh
Priority to RU2017113775A priority patent/RU2017113775A/ru
Priority to KR1020177008203A priority patent/KR20170055492A/ko
Priority to AU2015320230A priority patent/AU2015320230B2/en
Publication of CN105497876A publication Critical patent/CN105497876A/zh
Publication of CN105497876B publication Critical patent/CN105497876B/zh
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201410529437.4A 2014-09-24 2014-09-24 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 Active CN105497876B (zh)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN201410529437.4A CN105497876B (zh) 2014-09-24 2014-09-24 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN201580050316.4A CN110337304A (zh) 2014-09-24 2015-09-06 神经调节蛋白预防、治疗或延迟室性心律失常的用途及其组合物
KR1020177008203A KR20170055492A (ko) 2014-09-24 2015-09-06 심실 부정맥의 예방, 치료 또는 지연에 있어서의 뉴레귤린의 용도 및 그의 조성물
CA2961813A CA2961813A1 (en) 2014-09-24 2015-09-06 Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia, and composition thereof
EP15845381.1A EP3199174B1 (en) 2014-09-24 2015-09-06 Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia
PCT/CN2015/088972 WO2016045493A1 (zh) 2014-09-24 2015-09-06 神经调节蛋白预防、治疗或延迟室性心律失常的用途及其组合物
US15/513,939 US10441633B2 (en) 2014-09-24 2015-09-06 Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia, and composition thereof
RU2017113775A RU2017113775A (ru) 2014-09-24 2015-09-06 Применение нейрегулина в профилактике, лечении или отсрочке развития желудочковой аритмии и его композиция
JP2017516166A JP2017530127A (ja) 2014-09-24 2015-09-06 心室性不整脈の予防、治療、又は遅延におけるニューレグリンの使用、及びその組成物
AU2015320230A AU2015320230B2 (en) 2014-09-24 2015-09-06 Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia, and composition thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410529437.4A CN105497876B (zh) 2014-09-24 2014-09-24 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物

Publications (2)

Publication Number Publication Date
CN105497876A CN105497876A (zh) 2016-04-20
CN105497876B true CN105497876B (zh) 2021-01-15

Family

ID=55580273

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410529437.4A Active CN105497876B (zh) 2014-09-24 2014-09-24 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN201580050316.4A Pending CN110337304A (zh) 2014-09-24 2015-09-06 神经调节蛋白预防、治疗或延迟室性心律失常的用途及其组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580050316.4A Pending CN110337304A (zh) 2014-09-24 2015-09-06 神经调节蛋白预防、治疗或延迟室性心律失常的用途及其组合物

Country Status (9)

Country Link
US (1) US10441633B2 (https=)
EP (1) EP3199174B1 (https=)
JP (1) JP2017530127A (https=)
KR (1) KR20170055492A (https=)
CN (2) CN105497876B (https=)
AU (1) AU2015320230B2 (https=)
CA (1) CA2961813A1 (https=)
RU (1) RU2017113775A (https=)
WO (1) WO2016045493A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2530526T3 (es) 2005-12-30 2015-03-03 Zensun Shanghai Science And Technology Ltd Liberación extendida de neurregulina para mejorar la función cardíaca
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
AU2012392119B2 (en) 2012-10-08 2018-07-26 Zensun (Shanghai) Science & Technology, Co. Ltd. Compositions and methods for treating heart failure in diabetic patients
EP3895724B1 (en) 2013-05-22 2025-06-25 Zensun (Shanghai) Science and Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
US12295930B2 (en) * 2018-08-14 2025-05-13 Emory University Inducing proliferation of cardiomyocytes and therapeutic uses related thereto
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
JP2022547335A (ja) * 2019-09-16 2022-11-11 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． 組換えヒトニューレグリン誘導体及びその使用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
CN1655804A (zh) * 2002-05-24 2005-08-17 上海泽生科技开发有限公司 神经调节蛋白用于心血管疾病治疗的方法和组合物
CN101310766A (zh) * 2007-05-25 2008-11-26 上海泽生科技开发有限公司 神经调节蛋白的新用途
US8815593B2 (en) * 2008-11-03 2014-08-26 University Of Washington Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AU745324B2 (en) 1997-10-14 2002-03-21 Cenes Pharmaceuticals, Inc. Therapeutic methods comprising use of a neuregulin
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
EP1850841A1 (en) 2005-01-20 2007-11-07 Janssen Pharmaceutica N.V. Methods for qt interval control
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
ES2530526T3 (es) 2005-12-30 2015-03-03 Zensun Shanghai Science And Technology Ltd Liberación extendida de neurregulina para mejorar la función cardíaca
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
EP2370093A4 (en) 2008-11-28 2012-08-29 Zensun Shanghai Science And Technology Ltd NEUREGULIN AND CARDIAC STEM CELLS
EP2370458B1 (en) 2008-11-28 2014-10-15 Zensun (Shanghai) Science and Technology Limited Neuregulin peptides and their use
ES2748886T3 (es) 2009-06-09 2020-03-18 Zensun Shanghai Science & Tech Co Ltd Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
ES2575125T3 (es) 2009-06-09 2016-06-24 Zensun (Shanghai) Science And Technology Limited Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2011119836A1 (en) * 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
US20120028992A1 (en) * 2010-08-02 2012-02-02 Brown Arthur M Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals
WO2012054718A2 (en) 2010-10-22 2012-04-26 The General Hospital Corporation Treating long qt syndrome
CN102302552A (zh) * 2011-08-31 2012-01-04 朱明军 一种治疗心律失常的胶囊及其制备方法
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
AU2012392119B2 (en) 2012-10-08 2018-07-26 Zensun (Shanghai) Science & Technology, Co. Ltd. Compositions and methods for treating heart failure in diabetic patients
EP3895724B1 (en) 2013-05-22 2025-06-25 Zensun (Shanghai) Science and Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
EP3027190A1 (en) 2013-08-01 2016-06-08 Gilead Sciences, Inc. Compound and methods for treating long qt syndrome
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1655804A (zh) * 2002-05-24 2005-08-17 上海泽生科技开发有限公司 神经调节蛋白用于心血管疾病治疗的方法和组合物
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
CN101310766A (zh) * 2007-05-25 2008-11-26 上海泽生科技开发有限公司 神经调节蛋白的新用途
US8815593B2 (en) * 2008-11-03 2014-08-26 University Of Washington Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Improvement of cardiac function and reversal of gap junction remodeling by Neuregulin-1β in volume-overloaded rats with heart failure;Wang XH等;《J Geriatr Cardiol》;20120630;第9卷(第2期);第172-179页 *
Neuregulin-1 suppresses muscarinic receptor expression and acetylcholine-activated muscarinic K+ channels in cardiac myocytes;Ford BD等;《Biochem Biophys Res Commun》;20030805;第308卷(第1期);第23-28页 *
Neuregulin-1β对慢性收缩性心力衰竭的作用及机制探讨;刘超;《中国优秀硕士学位论文全文数据库医药卫生科技辑》;20100615(第6期);E062-54 *
Protective role of neuregulin-1 toward doxorubicin-induced myocardial toxicity;Liu YQ等;《Genet Mol Res》;20140618;第13卷(第2期);第4627-4634页 *
重组人纽兰格林治疗慢性收缩性心力衰竭的研究;张小昊;《中国优秀硕士学位论文全文数据库医药卫生科技辑》;20090815(第8期);E062-17 *
随机、双盲、多中心、标准治疗基础上的安慰剂并行对照评价注射用重组人纽兰格林对慢性收缩性心力衰竭患者疗效与安全性的Ⅱ期临床观察;刘宁;《中国优秀硕士学位论文全文数据库医药卫生科技辑》;20120215(第2期);E062-87 *

Also Published As

Publication number Publication date
AU2015320230B2 (en) 2021-06-24
WO2016045493A1 (zh) 2016-03-31
RU2017113775A (ru) 2018-10-26
US20170368140A1 (en) 2017-12-28
AU2015320230A1 (en) 2017-03-30
US10441633B2 (en) 2019-10-15
JP2017530127A (ja) 2017-10-12
EP3199174B1 (en) 2022-04-13
CA2961813A1 (en) 2016-03-31
CN110337304A (zh) 2019-10-15
RU2017113775A3 (https=) 2019-04-04
EP3199174A4 (en) 2018-06-06
EP3199174A1 (en) 2017-08-02
CN105497876A (zh) 2016-04-20
KR20170055492A (ko) 2017-05-19

Similar Documents

Publication Publication Date Title
CN105497876B (zh) 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
JP7761964B2 (ja) 心不全の治療用組成物
AU2021258063B2 (en) Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
EP2440236B1 (en) Neuregulin based methods for treating heart failure
US20250262275A1 (en) Neuregulin based methods for treating heart failure
CN102159236A (zh) 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
CN112168953A (zh) 缓释纽兰格林治疗心力衰竭
AU2021225283A1 (en) Method for preventing, treating or delaying heart failure by using neuregulin, and composition
CN120018856A (zh) 神经调节蛋白及其应用
HK40086556A (en) Method for preventing, treating or delaying heart failure by using neuregulin, and composition
HK1241737B (en) Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant